| HRA006511
(Controlled Access)
|
Neoadjuvant therapy of ICIs plus stereotactic body radiotherapy (SBRT) has shown promising results in several types of solid tumours but not HCC. This is a phase Ib clinical trial of neoadjuvant SBRT plus PD-1 (tislelizumab) in HCC patients (pts). Prior to resection, pts receive 8 Gy x 3 fractions of SBRT together with 2 cycles of PD-1 with an interval of 3 weeks. HCC resection is scheduled 4 weeks after the second dose of PD-1, followed by adjuvant PD-1 for up to 1 year. We plan to enrol 20 participants in this trial. |
